We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other firms that took a hit on Friday. Wall Street’s main indices all finished in the green ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

The leaders of major Danish companies, including the CEO of Ozempic-maker Novo Nordisk, have met with the Danish Prime Minister after being summoned to discuss the country’s ongoing spat with ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK1,050.00. The company’s shares closed ...

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) fell 3.6% on Friday after the U.S. Department of Health and Human Services (HHS) announced that Ozempic and Wegovy are among 15 medications ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...